Literature DB >> 6099616

Thromboxane synthase inhibition combined with thromboxane receptor blockade: a step forward in antithrombotic strategy?

P Gresele, E Van Houtte, J Arnout, H Deckmyn, J Vermylen.   

Abstract

Mesh：

Substances：

Year:  1984        PMID： 6099616

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  6 in total

1.  Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.

Authors:  P Gresele; J Arnout; H Deckmyn; E Huybrechts; G Pieters; J Vermylen
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

Review 2.  Current issues in thrombosis prevention with antiplatelet drugs.

Authors:  G de Gaetano; C Cerletti; E Dejana; J Vermylen
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

3.  3D pharmacophore models for thromboxane A(2) receptor antagonists.

Authors:  Jing Wei; Yixi Liu; Songqing Wang
Journal:  J Mol Model       Date:  2009-03-05       Impact factor: 1.810

4.  Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.

Authors:  I S Watts; K A Wharton; B P White; P Lumley
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

Review 5.  Role of platelet inhibitor therapy in myocardial infarction.

Authors:  B Stein; V Fuster
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

6.  "In vitro" and "ex vivo" effects of picotamide, a combined thromboxane A2-synthase inhibitor and -receptor antagonist, on human platelets.

Authors:  M Berrettini; M De Cunto; P Parise; S Grasselli; G G Nenci
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.